Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328980 | 0.87 | CDK4 (0.49) | CTSACDK4CCNA2CCND1CDK2 | |
| SCHEMBL4329239 | 0.84 | MAPK1 (0.45) | MAPK1ROCK2ROCK1TACR3ADORA2A | |
| SCHEMBL4334591 | 0.84 | ROCK2 (0.48) | CTSAMAPK1ROCK2ROCK1TACR3 | |
| SCHEMBL13635761 | 0.83 | CDK4 (0.57) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL4341430 | 0.83 | CDK4 (0.51) | CTSACDK4CCNA2CCND1CDK2 | |
| SCHEMBL2858040 | 0.82 | CDK4 (0.60) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL5034342 | 0.80 | MAPK1 (0.51) | CDK2MAPK1ROCK2ROCK1 | |
| SCHEMBL2864604 | 0.79 | RAB9A (0.54) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL2861022 | 0.79 | KDR (0.50) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL4341021 | 0.77 | MAPT (0.49) | CDK4CCNA2CCND1CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | CTSA 4048/4885CDK4 103/4885CCNA2 398/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | CTSA 4048/4885CDK4 103/4885CCNA2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.